Opendata, web and dolomites

VALUE-Dx SIGNED

The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 VALUE-Dx project word cloud

Explore the words cloud of the VALUE-Dx project. It provides you a very rough idea of what is the project "VALUE-Dx" about.

psychosocial    acquired    hampered    made    technological    opinions    continuous    medicine    alignment    barriers    amr    healthcare    causing    alternative    algorithms    considerable    expert    economic    personalized    provides    stakeholder    benefit    variety    respiratory    antibiotic    steer    outcomes    optimal    modern    resistance    outcome    models    actual    interaction    diagnostics    losses    reverse    tests    designs    clinical    indicators    adaptive    quality    lives    fuelling    stratify    interests    spread    dx    public    innovative    efficient    transform    diagnostic    platform    limited    tract    appropriate    prescription    demonstrated    policy    pan    century    infrastructure    regulatory    daily    close    lack    ethical    strides    trial    patient    organisational    health    adoption    combat    community    antimicrobial    worldwide    acute    infections    last    medical    understand    recommendations    treatments    limit    advocacy    requirement    tested    laboratory    antibiotics    arti    generate    economical    specifications    ca    threatening   

Project "VALUE-Dx" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITEIT ANTWERPEN 

Organization address
address: PRINSSTRAAT 13
city: ANTWERPEN
postcode: 2000
website: www.ua.ac.be

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Belgium [BE]
 Total cost 13˙739˙927 €
 EC max contribution 6˙799˙100 € (49%)
 Programme 1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
 Code Call H2020-JTI-IMI2-2017-13-two-stage
 Funding Scheme IMI2-RIA
 Starting year 2019
 Duration (year-month-day) from 2019-04-01   to  2023-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITEIT ANTWERPEN BE (ANTWERPEN) coordinator 2˙282˙957.00
2    THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD UK (OXFORD) participant 1˙716˙160.00
3    UNIVERSITAIR MEDISCH CENTRUM UTRECHT NL (UTRECHT) participant 730˙458.00
4    ACADEMISCH ZIEKENHUIS GRONINGEN NL (GRONINGEN) participant 305˙596.00
5    UNIVERSITA DEGLI STUDI DI VERONA IT (VERONA) participant 275˙409.00
6    THE HEALTH CORPORATION - RAMBAM IL (HAIFA) participant 226˙444.00
7    FONDAZIONE PENTA - FOR THE TREATMENT AND CARE OF CHILDREN WITH HIV ANDRELATED DISEASES - ONLUS IT (PADOVA) participant 189˙444.00
8    EUROPEAN SOCIETY CLINICAL MICROBIOLOGY INFECTIOUS DISEASES (EUROPAISCHE GESELLSCHAFT FUR KLINISCHE MIKROBIOLOGIE INFEKTIONSKRANKHEITEN) CH (BASEL) participant 184˙649.00
9    EUROPEAN RESPIRATORY SOCIETY CH (LAUSANNE) participant 144˙902.00
10    NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE UK (MANCHESTER) participant 137˙793.00
11    UNIVERSIDAD DE LA RIOJA ES (LA RIOJA) participant 136˙693.00
12    GESUNDHEIT OSTERREICH GMBH AT (WIEN) participant 88˙520.00
13    FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS CH (GENEVE) participant 77˙858.00
14    THE UNIVERSITY OF EDINBURGH UK (EDINBURGH) participant 75˙765.00
15    BERRY CONSULTANTS LLP UK (ABINGDON) participant 72˙411.00
16    BIOASTER FONDATION DE COOPERATION SCIENTIFIQUE FR (LYON) participant 66˙337.00
17    LUXEMBOURG INSTITUTE OF HEALTH LU (LUXEMBOURG) participant 37˙365.00
18    ZORGONDERZOEK NEDERLAND ZON NL (DEN HAAG) participant 34˙698.00
19    THE TRUSTEES OF BOSTON UNIVERSITY US (BOSTON MA) participant 15˙641.00
20    ACCELERATE DIAGNOSTICS SL ES (CASTELLDEFELS) participant 0.00
21    ALERE INTERNATIONAL LIMITED IE (GALWAY) participant 0.00
22    BD SWITZERLAND SARL CH (EYSINS) participant 0.00
23    BIO-RAD FR (MARNES-LA-COQUETTE) participant 0.00
24    BIOMERIEUX SA FR (Marcy l'Etoile) participant 0.00
25    JANSSEN PHARMACEUTICA NV BE (BEERSE) participant 0.00
26    THE WELLCOME TRUST LIMITED UK (LONDON) participant 0.00

Map

 Project objective

Antimicrobial resistance (AMR) is of great public health concern, causing numerous losses of lives worldwide and threatening to reverse many of the considerable strides modern medicine has made over the last century. There is a need to stratify antibiotic and alternative treatments in terms of the actual benefit for the patient, improving patient outcome and limit the impact on AMR. High quality, effective and appropriate diagnostic tests to steer appropriate use of antibiotics are available. However, implementation of these tests into daily healthcare practice is hampered due to lack of insight in the medical, technological and health economical value and limited knowledge about psychosocial, ethical, regulatory and organisational barriers to their implementation into clinical practice.

VALUE-Dx will define and understand these value indicators and barriers to adoption of diagnostics of Community-Acquired Acute Respiratory Tract Infections (CA-ARTI) in order to develop and improve health economic models to generate insight in the whole value of diagnostics and develop policy and regulatory recommendations. In addition, efficient clinical algorithms and user requirement specifications of tests will be developed fuelling the medical and technological value of CA-ARTI diagnostics. The value of diagnostics will be tested and demonstrated in a unique pan-European clinical and laboratory research infrastructure allowing for innovative adaptive trial designs to evaluate novel CA-ARTI diagnostics. Close and continuous interaction with the VALUE-Dx multi-stakeholder platform provides for optimal alignment of VALUE-Dx activities with stakeholder opinions, expert knowledge and interests.

A variety of dissemination and advocacy measures will promote wide-spread adoption of clinical and cost-effective innovative diagnostics to achieve more personalized, evidence-based antibiotic prescription in order to transform clinical practice, improve patient outcomes and combat AMR.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "VALUE-DX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "VALUE-DX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

RespiriNTM (2019)

Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugs

Read More  

EBOVAC3 (2018)

Bringing a prophylactic Ebola vaccine to licensure

Read More  

GNA NOW (2019)

NOVEL GRAM-NEGATIVE ANTIBIOTIC NOW

Read More